Trial · NCT02363283
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 14 of 14
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Response Rate Using Response Evaluation Criteria in Solid Tumors Version 1.1 | Treatment (Glembatumumab Vedotin) | Partial Response | 2 | Participants | |
| Overall Response Rate Using Response Evaluation Criteria in Solid Tumors Version 1.1 | Treatment (Glembatumumab Vedotin) | Stable Disease | 18 | Participants | |
| Overall Response Rate Using Response Evaluation Criteria in Solid Tumors Version 1.1 | Treatment (Glembatumumab Vedotin) | Disease Progression | 14 | Participants | |
| Overall Response Rate Using Response Evaluation Criteria in Solid Tumors Version 1.1 | Treatment (Glembatumumab Vedotin) | Unknown | 1 | Participants | |
| The Number of Participants With Change in Glycoprotein NMB Expression on Tumor Tissue Via Immunohistochemistry | Treatment (Glembatumumab Vedotin) | 22 | Participants | ||
| Progression-free Survival | Treatment (Glembatumumab Vedotin) | 3.1 | 95% Confidence Interval 1.5 to 5.6 | months | |
| Number of Participants With Grade 3-4 Adverse Events According to the National Cancer Institute Common Toxicity Criteria Version 4.0 | Treatment (Glembatumumab Vedotin) | Neutropenia | 19 | Participants | |
| Number of Participants With Grade 3-4 Adverse Events According to the National Cancer Institute Common Toxicity Criteria Version 4.0 | Treatment (Glembatumumab Vedotin) | Thrombocytopenia | 1 | Participants | |
| Number of Participants With Grade 3-4 Adverse Events According to the National Cancer Institute Common Toxicity Criteria Version 4.0 | Treatment (Glembatumumab Vedotin) | Diarrhea | 1 | Participants | |
| Number of Participants With Grade 3-4 Adverse Events According to the National Cancer Institute Common Toxicity Criteria Version 4.0 | Treatment (Glembatumumab Vedotin) | Constipation | 1 | Participants | |
| Number of Participants With Grade 3-4 Adverse Events According to the National Cancer Institute Common Toxicity Criteria Version 4.0 | Treatment (Glembatumumab Vedotin) | Vomiting | 1 | Participants | |
| Number of Participants With Grade 3-4 Adverse Events According to the National Cancer Institute Common Toxicity Criteria Version 4.0 | Treatment (Glembatumumab Vedotin) | Rash, maculopapular | 2 | Participants | |
| Number of Participants With Grade 3-4 Adverse Events According to the National Cancer Institute Common Toxicity Criteria Version 4.0 | Treatment (Glembatumumab Vedotin) | Pruritus | 2 | Participants | |
| Overall Survival | Treatment (Glembatumumab Vedotin) | 11.9 | 95% Confidence Interval 9 to 16.9 | months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02363283/results